Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial
OA Location
Author(s)
Zannad, F
Greenberg, B
Cleland, JGF
Gheorghiade, M
Van Veldhuisen, DJ
Type
Journal Article
Date Issued
2015-07-01
URI
DOI
ISSN
1388-9842
Publisher
WILEY-BLACKWELL
Start Page
735
End Page
742
Journal / Book Title
EUROPEAN JOURNAL OF HEART FAILURE
Volume
17
Issue
7
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000357519700014&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Subjects
Science & Technology
Life Sciences & Biomedicine
Cardiac & Cardiovascular Systems
Cardiovascular System & Cardiology
rivaroxaban
thrombin
antithrombotic
heart failure
coronary artery disease
THROMBIN GENERATION
MORTALITY
ANTICOAGULANTS
COAGULATION
MANAGEMENT
WARFARIN
OUTCOMES
ASPIRIN
IMPACT
Administration, Oral
Coronary Artery Disease
Double-Blind Method
Factor Xa Inhibitors
Heart Failure
Humans
Myocardial Infarction
Prospective Studies
Research Design
Risk Factors
Rivaroxaban
Stroke
Survival Rate
1102 Cardiovascular Medicine And Haematology
Cardiovascular System & Hematology
Publication Status
Published